samedan logo
 
 
 
spacer
home > ebr > spring 2008 > bridging vaccine translational research
PUBLICATIONS
European Biopharmaceutical Review

Bridging Vaccine Translational Research

Crawford Brown and Roger Lias of Eden Biodesign, Inc argue that in order for outsourced manufacturing strategies to work for vaccine development as they do for monoclonal antibodies, manufacturing development needs to account for the unique properties of vaccines

Interest in vaccines has never been greater, as shown by substantial high-profile private and public investment in the sector. For example, the market for vaccines for children and adolescents, is estimated to grow from $4.3 billion in 2006 to $16 billion by 2016 (1). Product development service providers, including contract manufacturing organisations (CMOs), can bridge vaccine translational research, enabling sponsors to rapidly develop and access new vaccines during early-stage clinical trials.

Many companies developing vaccines, unlike biotech companies developing monoclonal antibody products, need to make considerable capital investment in establishing their own manufacturing facilities, often at a time when capital is required to support clinical development. Table 1 shows a selection of top-tier biotechs that are developing vaccines and have established internal manufacturing capability.

This trend reflects, in part, the unique process and analytical challenges faced in developing each new vaccine, when compared to the platform approach that is more readily adopted for monoclonal antibody products (MABs). This article focuses on process design issues for the development of vaccines, comparing current commercial, technical and regulatory trends with the issues faced by companies developing highly characterised monoclonal antibodies.

RAPIDLY EXPANDING MARKET OPPORTUNITIES FOR BIOTECHS DEVELOPING VACCINES

The adage that ‘prevention is better than cure’ has been the basis for substantial interest in vaccines over the past few years from:

  • Governments
  • Pharmaceutical companies
  • Not-for-profit organisations

For governments struggling with rising healthcare costs, vaccines represent a cost-effective investment: for preventing illness; for government personnel rapidly mobilised for overseas operations; for use against pandemics, such as influenza; and more recently for preventing cancers caused by viral infections


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Crawford Brown, Chief Executive Officer, co-founded Eden Biodesign, Inc in 2000 from Celltech-Medeva where he was Director of Product Development and was responsible for developing and manufacturing the biotech product pipeline. Among his achievements Crawford managed and led a successful pan-European submission for a complex recombinant vaccine which included an EMEA sponsored pre-approval inspection. Crawford has held senior technical management positions in both biotech and pharmaceutical companies and has been actively engaged in commercial biopharmaceutical development for over 20 years. As well as leading the company, he retains a major role in Eden Biodesign’s consultancy services.

Dr Roger Lias is President of Eden Biodesign, Inc and Group Commercial Director. Roger’s responsibilities include identifying and establishing strategic business partnerships and expanding Eden Biodesign’s offer to the large North American biopharmaceutical sector. Prior to joining Eden, Roger held the position of Vice President, Sales and Business Development at Cytovance Biologics. At KBI BioPharma, a start-up contract biomanufacturing company, he played an active role in securing funding, building revenues and was responsible for identifying and establishing strategic business partnerships and new business relationships. Prior to this, he was Vice President, Business Development, at Diosynth where he had global responsibility and headed North American sales and marketing for Lonza Biologics.

spacer
Dr Crawford Brown
spacer
spacer
spacer
Dr Roger Lias
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Annual General Meeting of Gerresheimer AG approves dividend increase to EUR 1.20 per share

Duesseldorf, June 24, 2020—Payment of a dividend of EUR 1.20 per share was approved at the virtual Annual General Meeting of Gerresheimer AG.
More info >>

White Papers

Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands

West Pharmaceutical Services, Inc.

The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement